Anavex Gets FDA Clearance to Study Blarcamesine in Fragile X Syndrome

05:10 PM EDT, 10/15/2026 (MT Newswires) -- Anavex Life Sciences (AVXL) said late Thursday it received clearance from the US Food and Drug Administration to proceed with a clinical study of blarcamesine for Fragile X syndrome, a genetic condition associated with intellectual and developmental delays. Blarcamesine has previously received orphan drug designation from the FDA for the treatment of Fragile X syndrome, according to a statement.